8-Oxa-15-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17)-heptaen-14-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 8-Oxa-15-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17)-heptaen-14-one
• 英文别名: 8-oxa-15-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),2,4,6,9,11,13(17)-heptaen-14-one
• 化学式: C₁₅H₉NO₂
• 分子量: 235.24
• InChiKey: RJPZCIIPMLGXJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L
  申请人：King's College London

  公开号：EP3370774A1

  公开（公告）日：2018-09-12
• [EN] COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L<br/>[FR] COMBINAISON D'UN INHIBITEUR DE PARP AVEC UN INHIBITEUR DE GSK-3 OU DOT1L
  申请人：KING'S COLLEGE LONDON

  公开号：WO2017077326A1

  公开（公告）日：2017-05-11

  Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination. There is also described herein a method for selecting a therapy for a subject suffering from acute myeloid leukaemia, comprising determining whether a chromosomal abnormality at 11q23 is present in a sample obtained from the subject; wherein if the chromosomal abnormality at 11q23 is present in the sample, a therapy comprising combined administration of (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L)is selected for the subject.